Extra-medullary Plasmacytomas: A Case Series of Rare Hematological Tumors.

Solitary plasmacytoma is a rare malignant tumor belonging to the family of plasma cell proliferation. It accounts for a small portion of plasma cell tumors and remains a rare condition. We report three cases of rare extraosseous plasmacytomas in young patients.

Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide.

Erythropoietin-producing hepatocellular receptor A2 (EphA2), is a receptor tyrosine kinase involved in cell-cell interactions. It is known to be overexpressed in various tumors and is associated with poor prognosis. EphA2 has been proposed as a target for theranostic applications.

Development and Preclinical Evaluation of [At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer.

The application of prostate-specific membrane antigen (PSMA)-targeted α-therapy is a promising alternative to β-particle-based treatments. At is among the potential α-emitters that are favorable for this concept. Herein, At-based PSMA radiopharmaceuticals were designed, developed, and evaluated.

Biotechnology and In Vitro Culture as an Alternative System for Secondary Metabolite Production.

Medicinal plants are rich sources of bioactive compounds widely used as medicaments, food additives, perfumes, and agrochemicals. These secondary compounds are produced under stress conditions to carry out physiological tasks in plants. Secondary metabolites have a complex chemical structure with pharmacological properties.

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.

Prostate cancer (PC) is the second most common cancer among men, with 1.3 million yearly cases worldwide. Among those cancer-afflicted men, 30% will develop metastases and some will progress into metastatic castration-resistant prostate cancer (mCRPC), which is associated with a poor prognosis and median survival time that ranges from nine to 13 months.